J&J single-shot COVID-19 vaccine shows early promiseJ&J has announced early trial results that suggest its single-shot coronavirus vaccine provides a sustained response against the Share XJ&J single-shot COVID-19 vaccine shows early promisehttps://pharmaphorum.com/news/early-data-backs-jjs-single-shot-coronavirus-vaccine-phase-3-results-due-soon/
Celltrion closes in on COVID-19 antibody market after trial successSouth Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first Share XCelltrion closes in on COVID-19 antibody market after trial successhttps://pharmaphorum.com/news/celltrion-closes-in-on-covid-19-antibody-market-after-trial-success/
Could Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a Share XCould Lilly’s donanemab readout in Alzheimer’s boost Biogen’s prospects?https://pharmaphorum.com/news/could-lillys-alzheimers-drug-readout-boost-biogens-prospects/
Study says COVID-19 infection provides immunity, but people can transmit virusPrevious COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit Share XStudy says COVID-19 infection provides immunity, but people can transmit virushttps://pharmaphorum.com/news/study-says-covid-19-infection-provides-immunity-but-people-can-transmit-virus/
Synairgen starts dosing inhaled COVID-19 drug in phase 3 trialUK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19 patients, after Share XSynairgen starts dosing inhaled COVID-19 drug in phase 3 trialhttps://pharmaphorum.com/news/synairgen-starts-dosing-inhaled-covid-19-drug-in-phase-3-trial/
Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from Share XOral COVID-19 vaccine beckons, as ImmunityBio licenses iosBio techhttps://pharmaphorum.com/news/oral-covid-19-vaccine-beckons-as-immunitybio-licenses-iosbio-tech/
RNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsUS biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who Share XRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upshttps://pharmaphorum.com/news/rnai-biotech-atalanta-debuts-with-110m-plus-biogen-and-roche-cns-tie-ups/
Chi-Med agrees R&D partnership with InmageneChina’s Chi-Med and Inmagene Biopharmaceuticals have agreed a strategic partnership to develop preclinical drug candidates for potential treatment Share XChi-Med agrees R&D partnership with Inmagenehttps://pharmaphorum.com/news/chi-med-agrees-rd-partnership-with-inmagene/
Sanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnSanofi is to acquire UK biotech Kymab in a deal worth up to $1.45 billion as the big Share XSanofi buys UK’s Kymab and inflammatory disease hopeful for $1.45bnhttps://pharmaphorum.com/news/sanofi-buys-uks-kymab-and-inflammatory-disease-hopeful-for-1-45bn/
